Capabilities
One plant. Four capability lines. A catalog built to hold both.
Naprod manufactures oncology, anesthesia, and critical-care injectables — plus the tablets, capsules, and active ingredients that sit alongside them — from a single site in Tarapur, Maharashtra.
163 products live in the catalog today: 100 finished-dose formulations and 63 active pharmaceutical ingredients, produced under EU-GMP and WHO-GMP process controls.
Installed capacity
Six production lines, one site
Figures below come from Naprod's internal capacity draft, carried over from the company's own production planning documents ahead of this rebuild — not independently re-measured for this page.
-
3.5 M
Oncology lyophilized units / yr
-
3 M
Oncology liquid units / yr
-
30 M
Tablets / yr
-
15 M
Capsules / yr
-
10 M
General lyophilized units / yr
-
1 M
General liquid units / yr
Pending confirmation Figures pending confirmation — carried over from company draft/old-site copy, not yet reconfirmed for current output.
Product mix
What the plant actually produces
The 163-product catalog splits into finished dose form (FDF) products and active pharmaceutical ingredients (API), the latter supplied by group company MacChem. Every count below is drawn live from the product catalog.
| Dosage form | Products | Share of catalog |
|---|---|---|
| Active pharmaceutical ingredient (API) | 63 | 39% |
| Liquid injection | 57 | 35% |
| Lyophilized injection | 30 | 18% |
| Tablet | 8 | 5% |
| Other dosage form | 2 | 1% |
| Capsule | 2 | 1% |
| Ointment / cream | 1 | 1% |
| Total catalog | 163 | 100% |
Source: product catalog (163 products, live count). Every product also carries a market designation — see the Products page for the SRA / rest-of-world / domestic breakdown.
By capability
Three ways into the plant
Manufacturing is the base capability everything else builds on; lyophilization is the specialization behind Naprod's oncology injectables; R&D covers formulation and analytical development. Quality & Regulatory governs what the plant is permitted to ship, and where.
-
Manufacturing
The Tarapur, Maharashtra production floor behind all 163 products — 100 finished-dose formulations and 63 active pharmaceutical ingredients — run under EU-GMP and WHO-GMP process controls.
-
Lyophilization
Freeze-drying capacity purpose-built for the 30 lyophilized-injection products in the catalog, the dosage form most closely tied to Naprod’s oncology franchise.
-
Research & Development
Formulation and analytical development behind the catalog and the 24-product official pipeline, feeding future filings across SRA, ROW, and domestic markets.
-
Quality & Regulatory
21 international accreditations verified against official regulator lists — including EU-GMP, WHO-GMP, ANVISA, INVIMA, UAE MOHAP, and NHRA Bahrain.